Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases
- PMID: 30828564
- PMCID: PMC6384223
- DOI: 10.3389/fonc.2019.00070
Patterns of Bone Failure in Localized Prostate Cancer Previously Irradiated: The Preventive Role of External Radiotherapy on Pelvic Bone Metastases
Abstract
Introduction: External beam radiation therapy (EBRT) can cure localized prostate cancer (PCa) by sterilizing cancer cells in the prostate gland and surrounding tissues at risk of microscopic dissemination. We hypothesized that pelvic EBRT for localized PCa might have an unexpected prophylactic impact on the occurrence of pelvic bone metastases. Material and Methods: We reviewed the data of 332 metastatic PCa patients. We examined associations between the number (≤5 vs. >5) and the location of bone metastases (in-field vs. out-of-field), which occurred at first relapse, and a previous history of EBRT for PCa (EBRT vs. No-EBRT). Results: One hundred and ten patients M0 at baseline were eligible. Fifty-six patients (51%) were in the No-EBRT group, and 54 patients (49%) in the EBRT group. The proportion of patients who developed >5 bone metastases in the bony pelvis was higher in the No-EBRT group vs. the EBRT group: 10 patients (18%) vs. 2 patients (4%), respectively (p = 0.02). By multivariate analysis EBRT was associated with a lesser occurrence of patients who had >5 bone metastases in the bony pelvis (OR = 0.17 [95%CI, 0.04-0.87], p = 0.03). Time to occurrence of bone metastases ≥5 years (OR = 0.10 [95%CI, 0.05-0.19], p < 0.01), prior curative prostate treatment (OR = 0.58 [95%CI, 0.36-0.91], p = 0.02), >5 bone metastases in bony pelvis (OR = 2.61 [95%CI, 1.28-5.31], p < 0.01), >5 bone metastases out of bony pelvis (OR = 1.73 [95%CI, 1.09-2.76], p = 0.02) were all predictive of overall survival. Conclusion: Previous pelvic EBRT for PCa is associated with a lower number of pelvic bone metastases, which is associated with better overall survival.
Keywords: metastasis; patterns of failure; prostate cancer; radiotherapy; surgery.
Figures


Similar articles
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.Urol Oncol. 2017 May;35(5):234-242. doi: 10.1016/j.urolonc.2016.12.015. Epub 2017 Jan 19. Urol Oncol. 2017. PMID: 28110975
-
External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.Eur Urol. 2019 Feb;75(2):319-328. doi: 10.1016/j.eururo.2018.09.034. Epub 2018 Oct 4. Eur Urol. 2019. PMID: 30293908
-
External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.Oncol Rep. 2003 Mar-Apr;10(2):399-404. Oncol Rep. 2003. PMID: 12579279 Review.
-
Management strategies for locally advanced prostate cancer.Drugs Aging. 2006;23(2):119-29. doi: 10.2165/00002512-200623020-00003. Drugs Aging. 2006. PMID: 16536635 Review.
References
-
- D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 280:969–74. - PubMed
-
- Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, et al. . A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. (2013) 64:895–902. 10.1016/j.eururo.2013.03.033 - DOI - PubMed
-
- Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet Lond Engl. (2002) 360:103–6. 10.1016/S0140-6736(02)09408-4 - DOI - PubMed
-
- Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. . Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. (2015) 33:2143–50. 10.1200/JCO.2014.57.7510 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources